BETABiohacksAI is a research tool for informational purposes only. All outputs are computational hypothesis candidates — not confirmed mechanisms, not medical advice, and not a substitute for professional medical judgment. Independent experimental validation is always required.
BiohacksAI is an evolving scientific literature platform. New compounds and evidence are indexed continuously.
B
○

Imatinib Mesylate

A tyrosine kinase inhibitor and ANTINEOPLASTIC AGENT that inhibits the BCR-ABL kinase created by chromosome rearrangements in CHRONIC MYELOID LEUKEMIA and ACUTE LYMPHOBLASTIC LEUKEMIA, as well as PDG-derived tyrosine kinases that are overexpressed in gastrointestinal stromal tumors.

300+ PubMed studies analyzed · 5 RCTs · Evidence Score: 46.3

Research Domains

Imatinib Mesylate has been studied across 18 research domains including 🔬 Oncology, 🦠 Gut & Microbiome, ✨ Skin & Hair, 🛡️ Immunity, 😴 Sleep. The primary research focus is 🔬 Oncology with 39% of studies addressing this area.

Similar Compounds by Shared Targets

The following compounds share molecular targets with Imatinib Mesylate, based on binding affinity data from BindingDB and ChEMBL. Sorted by shared target overlap.

trequinsin
15 shared targets
Polidocanol
13 shared targets
Melengestrol
12 shared targets
Itraconazole
11 shared targets
Ethynodiol
14 shared targets
Deferasirox
12 shared targets
Azathioprine
13 shared targets
Thioinosine
10 shared targets
Methandrostenolone
9 shared targets
Beclomethasone
11 shared targets
Loading evidence profile...

This evidence profile for Imatinib Mesylate is generated deterministically from 300 PubMed-indexed studies. All data is corpus-verified with Merkle proofs. BiohacksAI does not provide medical advice. Always consult a healthcare professional before starting any supplement regimen.

Data source: PubMed/MEDLINE (NLM). Corpus version: current. Patent pending (EVE-PAT-2026-001). © 2026 Organiq Sweden AB.